265 related articles for article (PubMed ID: 36276066)
1. Platelet-promoting drug delivery efficiency for inhibition of tumor growth, metastasis, and recurrence.
Li X; Hu L; Tan C; Wang X; Ran Q; Chen L; Li Z
Front Oncol; 2022; 12():983874. PubMed ID: 36276066
[TBL] [Abstract][Full Text] [Related]
2. Smart transformable nanomedicines for cancer therapy.
Wang Y; Li S; Wang X; Chen Q; He Z; Luo C; Sun J
Biomaterials; 2021 Apr; 271():120737. PubMed ID: 33690103
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated-platelet-inspired nanomedicines for cancer therapy.
Geranpayehvaghei M; Dabirmanesh B; Khaledi M; Atabakhshi-Kashi M; Gao C; Taleb M; Zhang Y; Khajeh K; Nie G
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1702. PubMed ID: 33538125
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
5. Tumor vasculature-targeting nanomedicines.
Zhang Y; He J
Acta Biomater; 2021 Oct; 134():1-12. PubMed ID: 34271167
[TBL] [Abstract][Full Text] [Related]
6. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
7. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
8. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
10. Anticancer nanomedicines harnessing tumor microenvironmental components.
Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
[TBL] [Abstract][Full Text] [Related]
11. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
12. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
13. Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
Jiang Z; Chu Y; Zhan C
Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018
[TBL] [Abstract][Full Text] [Related]
14. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
[TBL] [Abstract][Full Text] [Related]
15. Combination antitumor therapy with targeted dual-nanomedicines.
Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
[TBL] [Abstract][Full Text] [Related]
16. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
[TBL] [Abstract][Full Text] [Related]
17. Strategies of engineering nanomedicines for tumor retention.
Qian X; Xu X; Wu Y; Wang J; Li J; Chen S; Wen J; Li Y; Zhang Z
J Control Release; 2022 Jun; 346():193-211. PubMed ID: 35447297
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Incorporated Nanomedicines for Cancer Therapy.
Wu SY; Wu FG; Chen X
Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395
[TBL] [Abstract][Full Text] [Related]
19. Self-Assembled Nanomedicines for Anticancer and Antibacterial Applications.
Zhou L; Qiu T; Lv F; Liu L; Ying J; Wang S
Adv Healthc Mater; 2018 Oct; 7(20):e1800670. PubMed ID: 30080319
[TBL] [Abstract][Full Text] [Related]
20. Active targeting strategy in nanomedicines using anti-EGFR ligands - A promising approach for cancer therapy and diagnosis.
Nguyen PV; Hervé-Aubert K; Chourpa I; Allard-Vannier E
Int J Pharm; 2021 Nov; 609():121134. PubMed ID: 34571073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
